{"dcterms:modified":"2026-10-19","dcterms:creator":"DataverseNO","@type":"ore:ResourceMap","schema:additionalType":"Dataverse OREMap Format v1.0.3","dvcore:generatedBy":{"@type":"schema:SoftwareApplication","schema:name":"Dataverse","schema:version":"6.11","schema:url":"https://github.com/iqss/dataverse"},"@id":"https://dataverse.no/api/datasets/export?exporter=OAI_ORE&persistentId=https://doi.org/10.18710/NUNHDF","ore:describes":{"contributor":[{"citation:contributorType":"Data Manager","citation:contributorName":"Dahl, Helene"},{"citation:contributorType":"Data Collector","citation:contributorName":"Sandnes, Kristina"},{"citation:contributorType":"Data Collector","citation:contributorName":"Welland, Natasha L."},{"citation:contributorType":"Data Collector","citation:contributorName":"Andresen, Iselin"},{"citation:contributorType":"Researcher","citation:contributorName":"Meyer, Klaus"},{"citation:contributorType":"Work Package Leader","citation:contributorName":"Lysne, Vegard"},{"citation:contributorType":"Researcher","citation:contributorName":"Marti, Hans-Peter"},{"citation:contributorType":"Project Leader","citation:contributorName":"Dierkes, Jutta"}],"citation:producer":{"citation:producerName":"University of Bergen","citation:producerAbbreviation":"UiB","citation:producerURL":"https://www.uib.no/en"},"citation:keyword":[{"citation:keywordValue":"Cystatin C","citation:keywordVocabulary":"MeSH","citation:keywordVocabularyURI":"https://www.ncbi.nlm.nih.gov/mesh/68055316"},{"citation:keywordValue":"Kidney Diseases","citation:keywordVocabulary":"MeSH","citation:keywordVocabularyURI":"https://www.ncbi.nlm.nih.gov/mesh/68007674"},{"citation:keywordValue":"Proteoform","citation:keywordVocabulary":"Mass spectrometry ontology","citation:keywordVocabularyURI":"http://purl.obolibrary.org/obo/PEFF_0001030"},{"citation:keywordValue":"chronic kidney disesase","citation:keywordVocabulary":"Human Disease Ontology","citation:keywordVocabularyURI":"http://purl.obolibrary.org/obo/DOID_784"}],"author":{"citation:authorName":"Dierkes, Jutta","citation:authorAffiliation":"University of Bergen","authorIdentifierScheme":"ORCID","authorIdentifier":"0000-0003-0663-877X"},"citation:dsDescription":[{"citation:dsDescriptionValue":"Supplementary dataset to 'Cystatin C proteoforms in chronic kidney disease'\r\n\r\nThis is a cross-sectional study on cystatin C proteoforms in patients with chronic kidney disease. The study was done at the University of Bergen and Haukeland University Hospital, Bergen, Norway. \r\nIn total, 157 patients with various degrees of chronic kidney disease were included, and proteoforms of cystatin C were measured with MALDI-TOF. This dataset contains supplementary information.","citation:dsDescriptionDate":"2021-04-24"},{"citation:dsDescriptionValue":"<p>    \r\n<p> ABSTRACT: \r\n<p> Cystatin C, a cysteine protease inhibitor, is used as a biomarker of renal function. It offers several advantages compared to creatinine, and formulas for the estimation of the glomerular filtration rate based on cystatin C have been developed. Recently, several proteoforms of cystatin C have been discovered, including an intact protein with a hydroxylated proline at the N-terminus, and N-terminal truncated forms. There is little knowledge about the biological significance of these proteoforms. \r\n<p> Methods: Cross-sectional study of patients with different stages of chronic renal disease (pre-dialysis n=53; hemodialysis n=51, renal transplant n=53). Measurement of cystatin C proteoforms by MALDI-TOF MS, assessment of medicine prescription using the first two levels of the Anatomical Therapeutic chemical system from patients’ records.\r\n<p>Results: Patients receiving hemodialysis had the highest cystatin C concentrations, followed by pre-dialysis patients and patients with a renal transplant. In all groups, the most common proteoforms were native cystatin C and CysC 3Pro-OH while the truncated forms made up 28%. The distribution of the different proteoforms was largely independent of renal function and total cystatin C. However, the use of corticosteroids (ATC-L02) and immunosuppressants (ATC-H04) considerably impacted the distribution of proteoforms. \r\n<p>Conclusion: The different proteoforms of cystatin C increased proportionally with total cystatin C in patients with chronic kidney disease. Prescription of corticosteroids and immunosuppressants had a significant effect on the distribution of proteoforms. The biological significance of these proteoforms remains to be determined.","citation:dsDescriptionDate":"2021-04-29"}],"software":{"citation:softwareName":"R studio"},"citation:datasetContact":{"citation:datasetContactName":"Dierkes, Jutta","citation:datasetContactAffiliation":"University of Bergen","citation:datasetContactEmail":"jutta.dierkes@uib.no"},"citation:distributor":{"citation:distributorName":"University of Bergen","citation:distributorAffiliation":"University of Bergen","citation:distributorURL":"https://dataverse.no/dataverse/uib"},"subject":"Medicine, Health and Life Sciences","biomedical:studyAssayOtherMeasurmentType":"protein proteoforms","biomedical:studyAssayPlatform":"ultrafleXtreme MALDI-TOF MS (Bruker)","title":"Replication data for: Cystatin C proteoforms in chronic kidney disease","language":"English","citation:relatedMaterial":["Gao, Jie; Meyer, Klaus; Borucki, Karin; Ueland, Per Magne. Multiplex Immuno-MALDI-TOF MS for Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to Inflammation and Renal Dysfunction. Anal. Chem. 2018, 90, 5, 3366–3373. https://doi.org/10.1021/acs.analchem.7b04975","Dierkes, J., Dahl, H., Lervaag Welland, N. et al. High rates of central obesity and sarcopenia in CKD irrespective of renal replacement therapy – an observational cross-sectional study. BMC Nephrol 19, 259 (2018). https://doi.org/10.1186/s12882-018-1055-6"],"biomedical:studyFactorType":"Biomarkers","biomedical:studyAssayOrganism":"Homo sapiens","dateOfDeposit":"2021-04-24","biomedical:studyDesignType":"Cross Sectional","biomedical:studyAssayTechnologyType":"Other","citation:productionPlace":"University of Bergen, and Haukeland University Hospital","citation:depositor":"Dierkes, Jutta","kindOfData":"clinical data","biomedical:studyAssayMeasurementType":"Other","@id":"https://doi.org/10.18710/NUNHDF","@type":["ore:Aggregation","schema:Dataset"],"schema:version":"1.1","schema:name":"Replication data for: Cystatin C proteoforms in chronic kidney disease","schema:dateModified":"Thu Sep 28 20:58:29 UTC 2023","schema:datePublished":"2021-04-30","schema:creativeWorkStatus":"RELEASED","schema:license":"http://creativecommons.org/publicdomain/zero/1.0","dvcore:fileTermsOfAccess":{"dvcore:fileRequestAccess":true},"schema:includedInDataCatalog":"DataverseNO","schema:isPartOf":{"schema:name":"University of Bergen","@id":"https://dataverse.no/dataverse/uib","schema:isPartOf":{"schema:name":"DataverseNO","@id":"https://dataverse.no/dataverse/root"}},"ore:aggregates":[{"schema:description":"README file for dataset 'Cystatin C proteoforms in chronic kidney disease*","schema:name":"00_README.txt","dvcore:restricted":false,"schema:version":1,"dvcore:datasetVersionId":3846,"@id":"doi:10.18710/NUNHDF/U3ISYX","schema:sameAs":"https://dataverse.no/api/access/datafile/:persistentId?persistentId=doi:10.18710/NUNHDF/U3ISYX","@type":"ore:AggregatedResource","schema:fileFormat":"text/plain","dvcore:filesize":8344,"dvcore:storageIdentifier":"S3://uit-dataverseno-prod01:1792254695f-399b1df3aa8b","dvcore:rootDataFileId":-1,"dvcore:checksum":{"@type":"http://www.w3.org/2001/04/xmldsig-more#md5","@value":"bde784cf73ea5a142ab6d1459a16b100"}},{"schema:description":"supplementary figure 1. Proportion of proteoforms of CysC with estimated GFR (eGFR) based on creatinine, cystatin C or both, and with total cystatin C in patients with pre-dialysis chronic kidney disease (CKD 3-5), patients receiving hemodialysis (HD) and in renal transplant recipients (KTX). ","schema:name":"Dahl_cysC_protforms_suppl_fig1.tif","dvcore:restricted":false,"schema:version":1,"dvcore:datasetVersionId":3846,"@id":"doi:10.18710/NUNHDF/0Z38Y1","schema:sameAs":"https://dataverse.no/api/access/datafile/:persistentId?persistentId=doi:10.18710/NUNHDF/0Z38Y1","@type":"ore:AggregatedResource","schema:fileFormat":"image/tiff","dvcore:filesize":602672,"dvcore:storageIdentifier":"S3://uit-dataverseno-prod01:17919098cdf-61655db9a3d9","dvcore:rootDataFileId":-1,"dvcore:checksum":{"@type":"http://www.w3.org/2001/04/xmldsig-more#md5","@value":"be6347ce7837c2f9982277f55a1d9019"}},{"schema:description":"Supplementary Table 2: Prescribed medications in the study population according to treatment group (CKD 3-5 chronic kidney disease stage 3-5, HD patients receiving hemodialysis, KTX renal transplant recipients)\r\nATC anatomical therapeutic chemical classification","schema:name":"PrescribedMedications.txt","dvcore:restricted":false,"schema:version":1,"dvcore:datasetVersionId":3846,"@id":"doi:10.18710/NUNHDF/FOUDZX","schema:sameAs":"https://dataverse.no/api/access/datafile/:persistentId?persistentId=doi:10.18710/NUNHDF/FOUDZX","@type":"ore:AggregatedResource","schema:fileFormat":"text/plain","dvcore:filesize":3805,"dvcore:storageIdentifier":"S3://uit-dataverseno-prod01:1791e5d4363-18856ba3a81f","dvcore:rootDataFileId":-1,"dvcore:checksum":{"@type":"http://www.w3.org/2001/04/xmldsig-more#md5","@value":"b8d14d84960f3380c872903e9a80031e"}},{"schema:description":"Characteristics of study population by CKD stage\r\n","schema:name":"StudyPopulation_characteristics_CKD.txt","dvcore:restricted":false,"schema:version":1,"dvcore:datasetVersionId":3846,"@id":"doi:10.18710/NUNHDF/BJOSZ0","schema:sameAs":"https://dataverse.no/api/access/datafile/:persistentId?persistentId=doi:10.18710/NUNHDF/BJOSZ0","@type":"ore:AggregatedResource","schema:fileFormat":"text/plain","dvcore:filesize":867,"dvcore:storageIdentifier":"S3://uit-dataverseno-prod01:17919092d74-0f1d4cf59ed1","dvcore:rootDataFileId":-1,"dvcore:checksum":{"@type":"http://www.w3.org/2001/04/xmldsig-more#md5","@value":"dc0dc0a4812fa706ec2dded7c6e80c32"}}],"schema:hasPart":["doi:10.18710/NUNHDF/U3ISYX","doi:10.18710/NUNHDF/0Z38Y1","doi:10.18710/NUNHDF/FOUDZX","doi:10.18710/NUNHDF/BJOSZ0"]},"@context":{"author":"http://purl.org/dc/terms/creator","authorIdentifier":"http://purl.org/spar/datacite/AgentIdentifier","authorIdentifierScheme":"http://purl.org/spar/datacite/AgentIdentifierScheme","biomedical":"https://dataverse.no/schema/biomedical#","citation":"https://dataverse.org/schema/citation/","content":"@value","contributor":"http://purl.org/dc/terms/contributor","dateOfDeposit":"http://purl.org/dc/terms/dateSubmitted","dcterms":"http://purl.org/dc/terms/","dvcore":"https://dataverse.org/schema/core#","kindOfData":"http://rdf-vocabulary.ddialliance.org/discovery#kindOfData","lang":"@language","language":"http://purl.org/dc/terms/language","ore":"http://www.openarchives.org/ore/terms/","personName":"https://schema.org/name","schema":"http://schema.org/","scheme":"http://www.w3.org/2004/02/skos/core#inScheme","software":"https://www.w3.org/TR/prov-o/#wasGeneratedBy","subject":"http://purl.org/dc/terms/subject","termName":"https://schema.org/name","title":"http://purl.org/dc/terms/title"}}